Industry Research Reports

Home > Reports > Pharma & Healthcare > Central Nervous System (CNS) Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Central Nervous System (CNS) Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published: 2024-01-09

Pages: 109 Pages

Report ld: 3020277

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson’s disease, dystonia, and essential tremor are central nervous system conditions. What they have in common is the loss of sufficient, intact nervous system circuits that orchestrate functions as varied as memory formation (in Alzheimer’s) or voluntary motion (in movement disorders).

The global market for Central Nervous System (CNS) Drug was estimated to be worth US$ 116250 million in 2023 and is forecast to a readjusted size of US$ 179630 million by 2030 with a CAGR of 7.0% during the forecast period 2024-2030

Central Nervous System (CNS) Drug Market Size

M= millions and B=billions

The presence of strong pipeline products is expected to drive the central nervous system therapeutics market over the forecast period. Major pharmaceutical companies are focusing on new treatments to prevent or improve symptoms of neurological diseases.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Central Nervous System (CNS) Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Central Nervous System (CNS) Drug by region & country, by Type, and by Application.

The Central Nervous System (CNS) Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Central Nervous System (CNS) Drug.

Market Segmentation

Report Metric
Details
Report Title
Central Nervous System (CNS) Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 179630 million
CAGR(2024-2030)
7%
Market Size Available for Years
2019-2030
Global Central Nervous System (CNS) Drug Companies Covered
Johnson & Johnson, Pfizer Inc, Novartis AG, GSK, Eli Lilly, Teva, Otsuka Pharmaceutical Co., Ltd, Biogen Inc, Boehringer Ingelheim, Roche, UCB, Tekeda, Shanghai Fosun, Jiangsu Nhwa Pharmaceutical Co., Ltd.
Global Central Nervous System (CNS) Drug Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Central Nervous System (CNS) Drug Market, Segment by Type
Prescription Drugs

OTC
Global Central Nervous System (CNS) Drug Market, Segment by Application
MS Therapeutics

Antipsychotic Drugs

Depression Drugs

Epilepsy Drugs

Others
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Central Nervous System (CNS) Drug manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Central Nervous System (CNS) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Central Nervous System (CNS) Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Central Nervous System (CNS) Drug Product Introduction
    1.2 Global Central Nervous System (CNS) Drug Market Size Forecast
    1.3 Central Nervous System (CNS) Drug Market Trends & Drivers
        1.3.1 Central Nervous System (CNS) Drug Industry Trends
        1.3.2 Central Nervous System (CNS) Drug Market Drivers & Opportunity
        1.3.3 Central Nervous System (CNS) Drug Market Challenges
        1.3.4 Central Nervous System (CNS) Drug Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Central Nervous System (CNS) Drug Players Revenue Ranking (2023)
    2.2 Global Central Nervous System (CNS) Drug Revenue by Company (2019-2024)
    2.3 Key Companies Central Nervous System (CNS) Drug Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Central Nervous System (CNS) Drug Product Offered
    2.5 Key Companies Time to Begin Mass Production of Central Nervous System (CNS) Drug
    2.6 Central Nervous System (CNS) Drug Market Competitive Analysis
        2.6.1 Central Nervous System (CNS) Drug Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Central Nervous System (CNS) Drug Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Central Nervous System (CNS) Drug as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Prescription Drugs
        3.1.2 OTC
    3.2 Global Central Nervous System (CNS) Drug Sales Value by Type
        3.2.1 Global Central Nervous System (CNS) Drug Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Central Nervous System (CNS) Drug Sales Value, by Type (2019-2030)
        3.2.3 Global Central Nervous System (CNS) Drug Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 MS Therapeutics
        4.1.2 Antipsychotic Drugs
        4.1.3 Depression Drugs
        4.1.4 Epilepsy Drugs
        4.1.5 Others
    4.2 Global Central Nervous System (CNS) Drug Sales Value by Application
        4.2.1 Global Central Nervous System (CNS) Drug Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Central Nervous System (CNS) Drug Sales Value, by Application (2019-2030)
        4.2.3 Global Central Nervous System (CNS) Drug Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Central Nervous System (CNS) Drug Sales Value by Region
        5.1.1 Global Central Nervous System (CNS) Drug Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Central Nervous System (CNS) Drug Sales Value by Region (2019-2024)
        5.1.3 Global Central Nervous System (CNS) Drug Sales Value by Region (2025-2030)
        5.1.4 Global Central Nervous System (CNS) Drug Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Central Nervous System (CNS) Drug Sales Value, 2019-2030
        5.2.2 North America Central Nervous System (CNS) Drug Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Central Nervous System (CNS) Drug Sales Value, 2019-2030
        5.3.2 Europe Central Nervous System (CNS) Drug Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Central Nervous System (CNS) Drug Sales Value, 2019-2030
        5.4.2 Asia Pacific Central Nervous System (CNS) Drug Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Central Nervous System (CNS) Drug Sales Value, 2019-2030
        5.5.2 South America Central Nervous System (CNS) Drug Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Central Nervous System (CNS) Drug Sales Value, 2019-2030
        5.6.2 Middle East & Africa Central Nervous System (CNS) Drug Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Central Nervous System (CNS) Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Central Nervous System (CNS) Drug Sales Value
    6.3 United States
        6.3.1 United States Central Nervous System (CNS) Drug Sales Value, 2019-2030
        6.3.2 United States Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Central Nervous System (CNS) Drug Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Central Nervous System (CNS) Drug Sales Value, 2019-2030
        6.4.2 Europe Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Central Nervous System (CNS) Drug Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Central Nervous System (CNS) Drug Sales Value, 2019-2030
        6.5.2 China Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Central Nervous System (CNS) Drug Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Central Nervous System (CNS) Drug Sales Value, 2019-2030
        6.6.2 Japan Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Central Nervous System (CNS) Drug Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Central Nervous System (CNS) Drug Sales Value, 2019-2030
        6.7.2 South Korea Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Central Nervous System (CNS) Drug Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Central Nervous System (CNS) Drug Sales Value, 2019-2030
        6.8.2 Southeast Asia Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Central Nervous System (CNS) Drug Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Central Nervous System (CNS) Drug Sales Value, 2019-2030
        6.9.2 India Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Central Nervous System (CNS) Drug Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Johnson & Johnson
        7.1.1 Johnson & Johnson Profile
        7.1.2 Johnson & Johnson Main Business
        7.1.3 Johnson & Johnson Central Nervous System (CNS) Drug Products, Services and Solutions
        7.1.4 Johnson & Johnson Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.1.5 Johnson & Johnson Recent Developments
    7.2 Pfizer Inc
        7.2.1 Pfizer Inc Profile
        7.2.2 Pfizer Inc Main Business
        7.2.3 Pfizer Inc Central Nervous System (CNS) Drug Products, Services and Solutions
        7.2.4 Pfizer Inc Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.2.5 Pfizer Inc Recent Developments
    7.3 Novartis AG
        7.3.1 Novartis AG Profile
        7.3.2 Novartis AG Main Business
        7.3.3 Novartis AG Central Nervous System (CNS) Drug Products, Services and Solutions
        7.3.4 Novartis AG Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.3.5 GSK Recent Developments
    7.4 GSK
        7.4.1 GSK Profile
        7.4.2 GSK Main Business
        7.4.3 GSK Central Nervous System (CNS) Drug Products, Services and Solutions
        7.4.4 GSK Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.4.5 GSK Recent Developments
    7.5 Eli Lilly
        7.5.1 Eli Lilly Profile
        7.5.2 Eli Lilly Main Business
        7.5.3 Eli Lilly Central Nervous System (CNS) Drug Products, Services and Solutions
        7.5.4 Eli Lilly Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.5.5 Eli Lilly Recent Developments
    7.6 Teva
        7.6.1 Teva Profile
        7.6.2 Teva Main Business
        7.6.3 Teva Central Nervous System (CNS) Drug Products, Services and Solutions
        7.6.4 Teva Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.6.5 Teva Recent Developments
    7.7 Otsuka Pharmaceutical Co., Ltd
        7.7.1 Otsuka Pharmaceutical Co., Ltd Profile
        7.7.2 Otsuka Pharmaceutical Co., Ltd Main Business
        7.7.3 Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Products, Services and Solutions
        7.7.4 Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.7.5 Otsuka Pharmaceutical Co., Ltd Recent Developments
    7.8 Biogen Inc
        7.8.1 Biogen Inc Profile
        7.8.2 Biogen Inc Main Business
        7.8.3 Biogen Inc Central Nervous System (CNS) Drug Products, Services and Solutions
        7.8.4 Biogen Inc Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.8.5 Biogen Inc Recent Developments
    7.9 Boehringer Ingelheim
        7.9.1 Boehringer Ingelheim Profile
        7.9.2 Boehringer Ingelheim Main Business
        7.9.3 Boehringer Ingelheim Central Nervous System (CNS) Drug Products, Services and Solutions
        7.9.4 Boehringer Ingelheim Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.9.5 Boehringer Ingelheim Recent Developments
    7.10 Roche
        7.10.1 Roche Profile
        7.10.2 Roche Main Business
        7.10.3 Roche Central Nervous System (CNS) Drug Products, Services and Solutions
        7.10.4 Roche Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.10.5 Roche Recent Developments
    7.11 UCB
        7.11.1 UCB Profile
        7.11.2 UCB Main Business
        7.11.3 UCB Central Nervous System (CNS) Drug Products, Services and Solutions
        7.11.4 UCB Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.11.5 UCB Recent Developments
    7.12 Tekeda
        7.12.1 Tekeda Profile
        7.12.2 Tekeda Main Business
        7.12.3 Tekeda Central Nervous System (CNS) Drug Products, Services and Solutions
        7.12.4 Tekeda Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.12.5 Tekeda Recent Developments
    7.13 Shanghai Fosun
        7.13.1 Shanghai Fosun Profile
        7.13.2 Shanghai Fosun Main Business
        7.13.3 Shanghai Fosun Central Nervous System (CNS) Drug Products, Services and Solutions
        7.13.4 Shanghai Fosun Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.13.5 Shanghai Fosun Recent Developments
    7.14 Jiangsu Nhwa Pharmaceutical Co., Ltd.
        7.14.1 Jiangsu Nhwa Pharmaceutical Co., Ltd. Profile
        7.14.2 Jiangsu Nhwa Pharmaceutical Co., Ltd. Main Business
        7.14.3 Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Products, Services and Solutions
        7.14.4 Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Revenue (US$ Million) & (2019-2024)
        7.14.5 Jiangsu Nhwa Pharmaceutical Co., Ltd. Recent Developments

 8 Industry Chain Analysis
    8.1 Central Nervous System (CNS) Drug Industrial Chain
    8.2 Central Nervous System (CNS) Drug Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Central Nervous System (CNS) Drug Sales Model
        8.5.2 Sales Channel
        8.5.3 Central Nervous System (CNS) Drug Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Central Nervous System (CNS) Drug Market Trends
    Table 2. Central Nervous System (CNS) Drug Market Drivers & Opportunity
    Table 3. Central Nervous System (CNS) Drug Market Challenges
    Table 4. Central Nervous System (CNS) Drug Market Restraints
    Table 5. Global Central Nervous System (CNS) Drug Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Central Nervous System (CNS) Drug Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Central Nervous System (CNS) Drug Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Central Nervous System (CNS) Drug Product Type
    Table 9. Key Companies Time to Begin Mass Production of Central Nervous System (CNS) Drug
    Table 10. Global Central Nervous System (CNS) Drug Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Central Nervous System (CNS) Drug as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Central Nervous System (CNS) Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Central Nervous System (CNS) Drug Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Central Nervous System (CNS) Drug Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Central Nervous System (CNS) Drug Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Central Nervous System (CNS) Drug Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Central Nervous System (CNS) Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Central Nervous System (CNS) Drug Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Central Nervous System (CNS) Drug Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Central Nervous System (CNS) Drug Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Central Nervous System (CNS) Drug Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Central Nervous System (CNS) Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Central Nervous System (CNS) Drug Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Central Nervous System (CNS) Drug Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Central Nervous System (CNS) Drug Sales Value by Region (2019-2024) & (%)
    Table 27. Global Central Nervous System (CNS) Drug Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Central Nervous System (CNS) Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Central Nervous System (CNS) Drug Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Central Nervous System (CNS) Drug Sales Value, (2025-2030) & (US$ Million)
    Table 31. Johnson & Johnson Basic Information List
    Table 32. Johnson & Johnson Description and Business Overview
    Table 33. Johnson & Johnson Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of Johnson & Johnson (2019-2024)
    Table 35. Johnson & Johnson Recent Developments
    Table 36. Pfizer Inc Basic Information List
    Table 37. Pfizer Inc Description and Business Overview
    Table 38. Pfizer Inc Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of Pfizer Inc (2019-2024)
    Table 40. Pfizer Inc Recent Developments
    Table 41. Novartis AG Basic Information List
    Table 42. Novartis AG Description and Business Overview
    Table 43. Novartis AG Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of Novartis AG (2019-2024)
    Table 45. Novartis AG Recent Developments
    Table 46. GSK Basic Information List
    Table 47. GSK Description and Business Overview
    Table 48. GSK Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of GSK (2019-2024)
    Table 50. GSK Recent Developments
    Table 51. Eli Lilly Basic Information List
    Table 52. Eli Lilly Description and Business Overview
    Table 53. Eli Lilly Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of Eli Lilly (2019-2024)
    Table 55. Eli Lilly Recent Developments
    Table 56. Teva Basic Information List
    Table 57. Teva Description and Business Overview
    Table 58. Teva Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of Teva (2019-2024)
    Table 60. Teva Recent Developments
    Table 61. Otsuka Pharmaceutical Co., Ltd Basic Information List
    Table 62. Otsuka Pharmaceutical Co., Ltd Description and Business Overview
    Table 63. Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of Otsuka Pharmaceutical Co., Ltd (2019-2024)
    Table 65. Otsuka Pharmaceutical Co., Ltd Recent Developments
    Table 66. Biogen Inc Basic Information List
    Table 67. Biogen Inc Description and Business Overview
    Table 68. Biogen Inc Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of Biogen Inc (2019-2024)
    Table 70. Biogen Inc Recent Developments
    Table 71. Boehringer Ingelheim Basic Information List
    Table 72. Boehringer Ingelheim Description and Business Overview
    Table 73. Boehringer Ingelheim Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of Boehringer Ingelheim (2019-2024)
    Table 75. Boehringer Ingelheim Recent Developments
    Table 76. Roche Basic Information List
    Table 77. Roche Description and Business Overview
    Table 78. Roche Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of Roche (2019-2024)
    Table 80. Roche Recent Developments
    Table 81. UCB Basic Information List
    Table 82. UCB Description and Business Overview
    Table 83. UCB Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of UCB (2019-2024)
    Table 85. UCB Recent Developments
    Table 86. Tekeda Basic Information List
    Table 87. Tekeda Description and Business Overview
    Table 88. Tekeda Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of Tekeda (2019-2024)
    Table 90. Tekeda Recent Developments
    Table 91. Shanghai Fosun Basic Information List
    Table 92. Shanghai Fosun Description and Business Overview
    Table 93. Shanghai Fosun Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of Shanghai Fosun (2019-2024)
    Table 95. Shanghai Fosun Recent Developments
    Table 96. Jiangsu Nhwa Pharmaceutical Co., Ltd. Basic Information List
    Table 97. Jiangsu Nhwa Pharmaceutical Co., Ltd. Description and Business Overview
    Table 98. Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Central Nervous System (CNS) Drug Business of Jiangsu Nhwa Pharmaceutical Co., Ltd. (2019-2024)
    Table 100. Jiangsu Nhwa Pharmaceutical Co., Ltd. Recent Developments
    Table 101. Key Raw Materials Lists
    Table 102. Raw Materials Key Suppliers Lists
    Table 103. Central Nervous System (CNS) Drug Downstream Customers
    Table 104. Central Nervous System (CNS) Drug Distributors List
    Table 105. Research Programs/Design for This Report
    Table 106. Key Data Information from Secondary Sources
    Table 107. Key Data Information from Primary Sources
    Table 108. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Central Nervous System (CNS) Drug Product Picture
    Figure 2. Global Central Nervous System (CNS) Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Central Nervous System (CNS) Drug Sales Value (2019-2030) & (US$ Million)
    Figure 4. Central Nervous System (CNS) Drug Report Years Considered
    Figure 5. Global Central Nervous System (CNS) Drug Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Central Nervous System (CNS) Drug Revenue in 2023
    Figure 7. Central Nervous System (CNS) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Prescription Drugs Picture
    Figure 9. OTC Picture
    Figure 10. Global Central Nervous System (CNS) Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 11. Global Central Nervous System (CNS) Drug Sales Value Market Share by Type, 2023 & 2030
    Figure 12. Product Picture of MS Therapeutics
    Figure 13. Product Picture of Antipsychotic Drugs
    Figure 14. Product Picture of Depression Drugs
    Figure 15. Product Picture of Epilepsy Drugs
    Figure 16. Product Picture of Others
    Figure 17. Global Central Nervous System (CNS) Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 18. Global Central Nervous System (CNS) Drug Sales Value Market Share by Application, 2023 & 2030
    Figure 19. North America Central Nervous System (CNS) Drug Sales Value (2019-2030) & (US$ Million)
    Figure 20. North America Central Nervous System (CNS) Drug Sales Value by Country (%), 2023 VS 2030
    Figure 21. Europe Central Nervous System (CNS) Drug Sales Value (2019-2030) & (US$ Million)
    Figure 22. Europe Central Nervous System (CNS) Drug Sales Value by Country (%), 2023 VS 2030
    Figure 23. Asia Pacific Central Nervous System (CNS) Drug Sales Value (2019-2030) & (US$ Million)
    Figure 24. Asia Pacific Central Nervous System (CNS) Drug Sales Value by Country (%), 2023 VS 2030
    Figure 25. South America Central Nervous System (CNS) Drug Sales Value (2019-2030) & (US$ Million)
    Figure 26. South America Central Nervous System (CNS) Drug Sales Value by Country (%), 2023 VS 2030
    Figure 27. Middle East & Africa Central Nervous System (CNS) Drug Sales Value (2019-2030) & (US$ Million)
    Figure 28. Middle East & Africa Central Nervous System (CNS) Drug Sales Value by Country (%), 2023 VS 2030
    Figure 29. Key Countries/Regions Central Nervous System (CNS) Drug Sales Value (%), (2019-2030)
    Figure 30. United States Central Nervous System (CNS) Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 31. United States Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
    Figure 32. United States Central Nervous System (CNS) Drug Sales Value by Application (%), 2023 VS 2030
    Figure 33. Europe Central Nervous System (CNS) Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 34. Europe Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
    Figure 35. Europe Central Nervous System (CNS) Drug Sales Value by Application (%), 2023 VS 2030
    Figure 36. China Central Nervous System (CNS) Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 37. China Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
    Figure 38. China Central Nervous System (CNS) Drug Sales Value by Application (%), 2023 VS 2030
    Figure 39. Japan Central Nervous System (CNS) Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 40. Japan Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
    Figure 41. Japan Central Nervous System (CNS) Drug Sales Value by Application (%), 2023 VS 2030
    Figure 42. South Korea Central Nervous System (CNS) Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 43. South Korea Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
    Figure 44. South Korea Central Nervous System (CNS) Drug Sales Value by Application (%), 2023 VS 2030
    Figure 45. Southeast Asia Central Nervous System (CNS) Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 46. Southeast Asia Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
    Figure 47. Southeast Asia Central Nervous System (CNS) Drug Sales Value by Application (%), 2023 VS 2030
    Figure 48. India Central Nervous System (CNS) Drug Sales Value, (2019-2030) & (US$ Million)
    Figure 49. India Central Nervous System (CNS) Drug Sales Value by Type (%), 2023 VS 2030
    Figure 50. India Central Nervous System (CNS) Drug Sales Value by Application (%), 2023 VS 2030
    Figure 51. Central Nervous System (CNS) Drug Industrial Chain
    Figure 52. Central Nervous System (CNS) Drug Manufacturing Cost Structure
    Figure 53. Channels of Distribution (Direct Sales, and Distribution)
    Figure 54. Bottom-up and Top-down Approaches for This Report
    Figure 55. Data Triangulation

Description

Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson’s disease, dystonia, and essential tremor are central nervous system conditions. What they have in common is the loss of sufficient, intact nervous system circuits that orchestrate functions as varied as memory formation (in Alzheimer’s) or voluntary motion (in movement disorders).

The global market for Central Nervous System (CNS) Drug was estimated to be worth US$ 116250 million in 2023 and is forecast to a readjusted size of US$ 179630 million by 2030 with a CAGR of 7.0% during the forecast period 2024-2030

The presence of strong pipeline products is expected to drive the central nervous system therapeutics market over the forecast period. Major pharmaceutical companies are focusing on new treatments to prevent or improve symptoms of neurological diseases.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Central Nervous System (CNS) Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Central Nervous System (CNS) Drug by region & country, by Type, and by Application.

The Central Nervous System (CNS) Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Central Nervous System (CNS) Drug.

Market Segmentation